Powerhouse Alliance Ushers in a New Era of Precision Medicine: XtalPi (02228.HK), Leman Biotech, and Dobot (02432.HK) Join Forces to Empower Cell Therapy with AI-Powered Humanoid Robots

Recently, Jingtai Holdings-P (02228), a leading AI company listed on the Hong Kong Stock Exchange under the 18C category, and its incubated cell therapy start-up Leman Biotech Co., Ltd, will partner with Dobot Robotics to establish a joint venture. Together, they aim to develop an AI humanoid robot-based cell therapy manufacturing platform. This collaboration marks a new phase of intelligence and automation in the cell therapy field, promising more efficient and precise treatment solutions for patients worldwide.

Zhitong Finance APP learned that cell therapy, as a frontier field in modern medicine, has already demonstrated tremendous potential in areas such as cancer, genetic diseases, and immune system disorders. However, the manufacturing process of cell therapy products is complex and highly reliant on manual operations. How to improve production efficiency and ensure consistent product quality has always been a challenge faced by the industry.

The collaboration among XtalPi, Leman Biotech, and Dobot Robotics is aimed at solving this challenge. By integrating XtalPi’s AI R&D platform, Leman Biotech’s cell therapy technology, and Dobot Robotics’ high-precision automation solutions, the three parties will jointly create an intelligent, fully automated cell therapy manufacturing platform.

XtalPi will leverage its leading AI algorithms and computational chemistry technology to rapidly screen and optimize the molecules and gene-editing tools required for cell therapy. By using AI to predict the activity and toxicity of drug molecules, XtalPi will further refine the design and production process of Leman Biotech's cell therapy products, providing safer and more efficient design solutions that significantly shorten the R&D cycle. Meanwhile, Dobot Robotics, through the precision operation of its robotic products, will promote the standardization and scalability of complex processes such as cell culture, gene editing, and product packaging, greatly improving production efficiency.

In fact, the AI humanoid robot-enabled cell therapy driven by this tripartite cooperation represents not only a technological breakthrough but also a revolution in the medical model. In the future, the research, development, and manufacturing of cell therapy products will become more efficient, precise, and accessible. This collaboration is expected to set a new benchmark for China's cell therapy industry and bring new hope to patients worldwide.